Clinical Trial Detail

NCT ID NCT03896269
Title CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

chronic myelomonocytic leukemia

myelodysplastic syndrome

Therapies

CPX-351

Age Groups: adult senior

No variant requirements are available.